Previous Close | 0.3830 |
Open | 0.3828 |
Bid | 0.0000 x 1100 |
Ask | 0.0000 x 3100 |
Day's Range | 0.3737 - 0.4600 |
52 Week Range | 0.2750 - 14.6100 |
Volume | |
Avg. Volume | 36,554,109 |
Market Cap | 35.295M |
Beta (5Y Monthly) | -1.68 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -19.0060 |
Earnings Date | Nov 14, 2022 - Nov 18, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.05 |
Subscribe to Yahoo Finance Plus to view Fair Value for EVFM
Evofem Biosciences, Inc., (EVFM) will hold an investor call as follows:
Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Evofem Biosciences.
Evofem Biosciences Inc's (NASDAQ: EVFM) Q2 Phexxi sales increased 42% Y/Y to $6.0 million, reflecting higher ex-factory sales and lower gross-to-net adjustments of 40%. The company's operating expense was reduced by 8% to $30 million and improved loss from operations by 16% to $(24) million. The U.S. government clarified that it would enforce federal law requiring group health plans and health insurance issuers to cover contraception at no cost to participants. In June, Evofem announced an agree